Back to Journals » Journal of Pain Research » Volume 6

Considerations in selecting rapid-onset opioids for the management of breakthrough pain

Authors Perelman M, Leake S

Received 26 March 2013

Accepted for publication 27 March 2013

Published 5 June 2013 Volume 2013:6 Pages 435—436

DOI https://doi.org/10.2147/JPR.S45774


Michael Perelman, Suzan Leake

Archimedes Pharma, Bedminister, NJ, USA

We read with great interest the recent publication by Smith.1 This article provides a valuable perspective on the selection of an agent to manage breakthrough pain. Smith recognizes the importance of a fast onset-of-action and the identification by Farrar et al2 of a 33% (often ≥2 point) change in the pain intensity difference as a measure of a ‘clinically important improvement’. For these reasons, Smith focuses on the various transmucosal fentanyl formulations that offer a rapid onset and he provides a nice summary of the key features of each of the available products.

View original paper by Howard S Smith.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]